Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting
In this real-world database, disparities in receiving 1st -line CDK4/6 inhibitors were seen by age, diagnosis stage, baseline performance status, comorbidity, and insurance status. In adjusted analysis, the use of 1st -line CDK4/6i plus ET yielded better PFS and OS rates than ET alone. Further efforts are essential to enhance equitable use of and access to this crucial drug class.
Authors
- Asal Pilehvari (ORCID: https://orcid.org/0000-0002-7793-7948)
- Gloribel Bonilla (ORCID: https://orcid.org/0000-0003-4272-1191)
- Roger T. Anderson (ORCID: https://orcid.org/0000-0001-8112-4117)
- Gretchen Kimmick (ORCID: https://orcid.org/0000-0001-7096-9624)
- Wen You (ORCID: https://orcid.org/0000-0003-3240-6526)
Institutions
- Duke Medical Center (US)
- University of Virginia Cancer Center
- University of Virginia (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1186/s13058-024-01902-w
- Citations
- 8
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- American Cancer Society
- Flatiron Health